Surtuin 1 as a potential prognostic biomarker in very elderly patients with colorectal cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Colorectal cancer (CRC) rate increases with aging. Aging-related proteins, such as sirtuins (SIRTs) may be a potential therapeutic target in the elderly patients with CRC. The clinical implications of SIRT1 and SIRT2 have not been reported for elderly patients with cancer. The aim of this study was to evaluate the impact of expression of SIRT1 and SIRT2 on clinical outcome in two extreme age groups of patients with CRC. Methods: The expression of SIRT1 and SIRT2 were evaluated in CRC tissues of 101 patients aged ≥ 80 years and 29 patients aged ≤ 40 years by immunohistochemistry. We defined the patients aged ≥ 80 years as the very elderly and patients aged ≤ 40 years as the young patients. Correlations between the expression of these proteins and clinicopathological features were analyzed. Results: The prognosis for the very elderly patients with high expressions of SIRT1 was significantly worse than that for patients showing low expression (median survival, 24.9 months vs. 38.6 months, p = 0.027) whereas high expression of SIRT2 better prognosis (median survival, 37.9 months vs. 17.3 months, p = 0.006). However, the young patients did not show any difference in prognosis according to expression of SIRT1 and SIRT2. In multivariate analysis, high SIRT1 expression retained statistical significance as a poor prognostic factor in the very elderly patients with CRC. Conclusions: The results suggest that high SIRT1 expression could be predictive of a poor outcome for very elderly patients with CRC.
Abstract
Background/Aims: Colorectal cancer (CRC) rate increases with aging. Aging-related proteins, such as sirtuins (SIRTs) may be a potential therapeutic target in the elderly patients with CRC. The clinical implications of SIRT1 and SIRT2 have not been reported for elderly patients with cancer. The aim of this study was to evaluate the impact of expression of SIRT1 and SIRT2 on clinical outcome in two extreme age groups of patients with CRC. Methods: The expression of SIRT1 and SIRT2 were evaluated in CRC tissues of 101 patients aged ≥ 80 years and 29 patients aged ≤ 40 years by immunohistochemistry. We defined the patients aged ≥ 80 years as the very elderly and patients aged ≤ 40 years as the young patients. Correlations between the expression of these proteins and clinicopathological features were analyzed. Results: The prognosis for the very elderly patients with high expressions of SIRT1 was significantly worse than that for patients showing low expression (median survival, 24.9 months vs. 38.6 months, p = 0.027) whereas high expression of SIRT2 better prognosis (median survival, 37.9 months vs. 17.3 months, p = 0.006). However, the young patients did not show any difference in prognosis according to expression of SIRT1 and SIRT2. In multivariate analysis, high SIRT1 expression retained statistical significance as a poor prognostic factor in the very elderly patients with CRC. Conclusions: The results suggest that high SIRT1 expression could be predictive of a poor outcome for very elderly patients with CRC.
참고문헌 (45)
- Guarente L, "Genetic pathways that regulate ageing in model organisms", Nature, 408, pp.255~262 (2000)
- Bosch-Presegue L, "The dual role of sirtuins in cancer", Genes Cancer, 2, pp.648~662 (2011)
- Roth M, "Sorting out functions of sirtuins in cancer", Oncogene, 33, pp.1609~1620 (2014)
- Chalkiadaki A, "Sirtuins mediate mammalian metabolic responses to nutrient availability", Nat Rev Endocrinol, 8, pp.287~296 (2012)
- Hall JA, "The sirtuin family’s role in aging and age-associated pathologies", J Clin Invest, 123, pp.973~979 (2013)
- Liu T, "The critical role of the class III histone deacetylase SIRT1 in cancer", Cancer Res, 69, pp.1702~1705 (2009)
- Cheon MG, "AK-1, a specific SIRT2 inhibitor, induces cell cycle arrest by downregulating Snail in HCT116 human colon carcinoma cells", Cancer Lett, 356(2 Pt B), pp.637~645 (2015)
- de Magalhaes JP, "How ageing processes influence cancer", Nat Rev Cancer, 13, pp.357~365 (2013)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- Siegel R, "Colorectal cancer statistics, 2014", CA Cancer J Clin, 64, pp.104~117 (2014)
- Huffman DM, "SIRT1 is significantly elevated in mouse and human prostate cancer", Cancer Res, 67, pp.6612~6618 (2007)
- Derr RS, "High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients", BMC Cancer, 14, pp.604~ (2014)
- Han L, "SIRT1 is highly expressed in brain metastasis tissues of non-small cell lung cancer(NSCLC)and in positive regulation of NSCLC cell migration", Int J Clin Exp Pathol, 6, pp.2357~2365 (2013)
- Chen W, "Roles of SIRT1 in leukemogenesis", Curr Opin Hematol, 20, pp.308~313 (2013)
- Ma MC, "SIRT1 overexpression is an independent prognosticator for patients with esophageal squamous cell carcinoma", J Cardiothorac Surg, 13, pp.25~ (2018)
- Hong WG, "The clinicopathological significance of SIRT1 expression in colon cancer : an immunohistochemical study and meta-analysis", Pathol Res Pract, 214, pp.1550~1555 (2018)
- Hiratsuka M, "Proteomics-based identification of differentially expressed genes in human gliomas : down-regulation of SIRT2 gene", Biochem Biophys Res Commun, 309, pp.558~566 (2003)
- Kim HS, "SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC", C activity, 2011, pp.20, 487~499
- Dan L, "The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells", Haematologica, 97, pp.551~559 (2012)
- Hou H, "Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ", J Clin Pathol, 65, pp.1088~1096 (2012)
- Wilking-Busch MJ, "Expression profile of SIRT2 in human melanoma and implications for sirtuin-based chemotherapy", Cell Cycle, 16, pp.574~577 (2017)
- Remmele W, "Recommendation for uniform definition of an immunoreactive score(IRS)for immunohistochemical estrogen receptor detection(ER-ICA)in breast cancer tissue", Pathologe, 8, pp.138~140 (1987)
- Meyerholz DK, "Principles and approaches for reproducible scoring of tissue stains in research", Lab Invest, 98, pp.844~855 (2018)
- Wu X, "Role of sirtuins in maintenance of genomic stability : relevance to cancer and healthy aging", DNA Cell Biol, 35, pp.542~575 (2016)
- Akbulut KG, "The role of melatonin, sirtuin2 and FoXO1 transcription factor in the aging process of colon in male rats", Biogerontology, 16, pp.99~108 (2015)
- Chen WY, "Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses", Cell, 123, pp.437~448 (2005)
- Lin Z, "The roles of SIRT1 in cancer", Genes Cancer, 4, pp.97~104 (2013)
- Lee JT, "SIRT1 : regulator of p53 deacetylation", Genes Cancer, 4, pp.112~117 (2013)
- Vaziri H, "hSIR2(SIRT1)functions as an NAD-dependent p53 deacetylase", Cell, 107, pp.149~159 (2001)
- Yi J, "SIRT1 and p53, effect on cancer, senescence and beyond", Biochim Biophys Acta, 1804, pp.1684~1689 (2010)
- 정원경, "SIRT1 Expression Is Associated with Good Prognosis in Colorectal Cancer", Journal of Pathology and Translational Medicine, 47(4), pp.332~339 (2013), 대한병리학회[DOI]
- Nosho K, "SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer", Mod Pathol, 22, pp.922~932 (2009)
- Anwar T, "Increased expression of SIRT2 is a novel marker of cellular senescence and is dependent on wild type p53 status", Cell Cycle, 15, pp.1883~1897 (2016)
- Ramakrishnan G, "Sirt2deacetylase is a novel AKT binding partner critical for AKT activation by insulin", J Biol Chem, 289, pp.6054~6066 (2014)
- Firestein R, "The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth", PLoS One, 3, pp.e2020~ (2008)
- Jang SH, "Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma", J Clin Pathol, 65, pp.735~739 (2012)
- Zu G, "Clinicopathological significance of SIRT1 expression in colorectal cancer : a systematic review and meta analysis", Int J Surg, 26, pp.32~37 (2016)
- Dryden SC, "Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle", Mol Cell Biol, 23, pp.3173~3185 (2003)
- North BJ, "The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase", Mol Cell, 11, pp.437~444 (2003)
- McGlynn LM, "SIRT2: tumour suppressor or tumour promoter in operable breast cancer?", Eur J Cancer, 50, pp.290~301 (2014)
- Seo KS, "SIRT2 regulates tumour hypoxia response by promoting HIF-1α hydroxylation", Oncogene, 34, pp.1354~1362 (2015)
- Liu PY, "The histone deacetylase SIRT2 stabilizes Myc oncoproteins", Cell Death Differ, 20, pp.503~514 (2013)
- Yang MH, "HDAC6 and SIRT2regulate the acetylation state and oncogenic activity of mutant K-RAS", Mol Cancer Res, 11, pp.1072~1077 (2013)
- Nguyen P, "SIRT2 interacts with β-catenin to inhibit Wnt signaling output in response to radiation-induced stress", Mol Cancer Res, 12, pp.1244~1253 (2014)
- Peck B, "SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2", Mol Cancer Ther, 9, pp.844~855 (2010)